Related content

A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer

By  

Medical Oncology, Vol. 24, Iss. 2, 2007-06 ,pp. : 137-146

Humana Press, Inc

Access to resources Recommend Favorite

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

By Chen Jianping   Smith Melissa   Kolinsky Kenneth   Adames Violeta   Mehta Nila   Fritzky Luke   Rashed Mohammad   Wheeldon Eric   Linn Michael   Higgins Brian  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 651-659

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

By Cassinello J.   López-Alvarez P.   Martínez-Guisado A.   Valladares M.   Huidobro G.   López R.   Bohn U.   Sevilla I.   Ballesteros P.   Jorge M.   Pérez-Carrión R.   Fernández J.   Dorta J.  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 37-43

Humana Press, Inc

Access to resources Recommend Favorite

Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth

By Takano Shingo   Kamiyama Hiroshi   Mashiko Ryota   Osuka Satoru   Ishikawa Eiichi   Matsumura Akira  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 177-185

Springer Publishing Company

Access to resources Recommend Favorite

Rapid Tumour Lysis Syndrome in a Metastatic Colorectal Cancer Increased by Treatment with Irinotecan (CPT-11)

By Boisseau M.   Bugat R.   Mahjoubi M.  

European Journal of Cancer, Vol. 32, Iss. 4, 1996-04 ,pp. : 737-738

Elsevier

Access to resources Recommend Favorite